Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer

Nabil Saba • 1 Jun 2026
ASCO 2026
Head and Neck Cancer Chemotherapy
NRG-HN015

Nabil Saba, MD, Emory University, Atlanta, GA, discusses the rationale and trial design of the NRG-HN015 trial (NCT07195734), a Phase II randomized study investigating the addition of chemo-immunotherapy or chemotherapy to standard salvage surgery in patients with locally recurrent head and neck cancer. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nabil Saba

ASCO guidelines update: systemic therapy sequencing in advanced thyroid cancer
3:09
ASCO guidelines update: systemic therapy sequencing in advanced thyroid cancer
Nabil Saba • 1 Jun 2026
INO-3107 and B-cell immunity: implications for HPV-associated cancers
1:29
INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba • 1 Jun 2026
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
3:02
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
Nabil Saba • 1 Jun 2026
DNA immunotherapy (INO-3107) in HPV-6 & 11 recurrent respiratory papillomatosis: long-term efficacy
2:42
DNA immunotherapy (INO-3107) in HPV-6 & 11 recurrent respiratory papillomatosis: long-term efficacy
Nabil Saba • 20 Oct 2025

Related Videos

Phase II study of FID-007 plus cetuximab in recurrent or metastatic HNSCC
1:04
Phase II study of FID-007 plus cetuximab in recurrent or metastatic HNSCC
Jacob Thomas • 31 May 2026
TARGET-HPV: neoadjuvant HPV16-targeted immunotherapy in oropharyngeal cancer
2:24
TARGET-HPV: neoadjuvant HPV16-targeted immunotherapy in oropharyngeal cancer
Ari Rosenberg • 31 May 2026
INO-3107 and B-cell immunity: implications for HPV-associated cancers
1:29
INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba • 1 Jun 2026
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
3:02
B-cell responses in recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107
Nabil Saba • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals